INSM – Insmed Incorporated

INSM — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.71

Margin Of Safety %

Put/Call OI Ratio

0.45

EPS Next Q Diff

0.73

EPS Last/This Y

3.61

EPS This/Next Y

3.48

Price

163.1

Target Price

214.79

Analyst Recom

1.1

Performance Q

-6.95

Upside

-237.4%

Beta

1.14

Ticker: INSM

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	INSM	143.11	0.50	0.22	49371
2026-03-10	INSM	143.85	0.50	0.13	49285
2026-03-11	INSM	139.31	0.50	1.99	49328
2026-03-12	INSM	139.58	0.51	6.69	49520
2026-03-13	INSM	139.52	0.51	6.54	49520
2026-03-17	INSM	143.93	0.52	0.08	49326
2026-03-18	INSM	142.74	0.52	0.05	49546
2026-03-19	INSM	143.89	0.52	0.05	49404
2026-03-20	INSM	136.03	0.50	0.17	49327
2026-03-23	INSM	143.99	0.52	0.05	34386
2026-03-24	INSM	139.15	0.50	0.92	35497
2026-03-25	INSM	148.31	0.53	1.21	40213
2026-03-26	INSM	147.53	0.55	0.14	41126
2026-03-27	INSM	145.35	0.55	2.03	41240
2026-03-30	INSM	153.35	0.56	0.29	41554
2026-03-31	INSM	164.14	0.56	1.33	41840
2026-04-01	INSM	166.01	0.56	1.47	41782
2026-04-02	INSM	162.52	0.56	0.73	41861
2026-04-06	INSM	163.94	0.45	1.64	42550
2026-04-07	INSM	163.16	0.45	0.29	42871
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	INSM	143.10	29.5	554.2	-2.86
2026-03-10	INSM	143.91	29.1	565.5	-2.85
2026-03-11	INSM	139.36	29.1	589.1	-2.85
2026-03-12	INSM	139.56	29.1	568.1	-2.85
2026-03-13	INSM	139.49	29.1	569.0	-2.85
2026-03-17	INSM	143.95	29.1	571.8	-2.85
2026-03-18	INSM	142.74	29.1	574.2	-2.85
2026-03-19	INSM	143.91	29.1	581.8	-2.85
2026-03-20	INSM	136.00	29.1	621.8	-2.85
2026-03-23	INSM	143.96	29.1	550.6	-2.85
2026-03-24	INSM	139.09	29.1	608.3	-2.85
2026-03-25	INSM	148.31	29.1	546.3	-2.85
2026-03-26	INSM	147.47	29.1	590.7	-2.85
2026-03-27	INSM	145.35	29.1	596.6	-2.85
2026-03-30	INSM	153.35	29.1	421.3	-2.89
2026-03-31	INSM	163.52	29.1	413.2	-2.89
2026-04-01	INSM	164.91	29.1	456.1	-2.89
2026-04-02	INSM	162.49	29.1	473.3	-2.89
2026-04-06	INSM	163.79	30.2	456.6	-2.81
2026-04-07	INSM	163.10	30.2	466.1	-2.81
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	INSM	-18.41	-0.62	5.39
2026-03-10	INSM	-18.41	-0.62	5.39
2026-03-11	INSM	-18.41	-0.62	5.29
2026-03-12	INSM	-18.41	-0.62	5.29
2026-03-13	INSM	-18.41	-0.62	5.29
2026-03-17	INSM	-16.02	-0.56	5.29
2026-03-18	INSM	-16.02	-0.56	5.29
2026-03-19	INSM	-16.02	-0.56	5.29
2026-03-20	INSM	-16.32	-0.56	5.29
2026-03-23	INSM	-16.32	-0.56	5.29
2026-03-24	INSM	-16.32	-0.56	5.29
2026-03-25	INSM	-16.32	-0.56	4.71
2026-03-26	INSM	-16.32	-0.56	4.71
2026-03-27	INSM	-16.32	-0.56	4.71
2026-03-30	INSM	-16.32	-0.55	4.71
2026-03-31	INSM	-16.87	-0.55	4.71
2026-04-01	INSM	-16.87	-0.55	4.71
2026-04-02	INSM	-16.87	-0.55	4.71
2026-04-06	INSM	-19.26	-0.56	4.71
2026-04-07	INSM	-19.26	-0.56	4.71
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.54

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-0.81

Insider Transactions

-19.26

Institutional Transactions

-0.56

Beta

1.14

Average Sales Estimate Current Quarter

303

Average Sales Estimate Next Quarter

385

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

23.3

Max Drawdown 5-Year %

-54.8

Target Price

214.79

P/E

Forward P/E

159.66

PEG

P/S

57.95

P/B

47.27

P/Free Cash Flow

EPS

-6.4

Average EPS Est. Cur. Y

-2.81

EPS Next Y. (Est.)

0.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-210.54

Relative Volume

0.53

Return on Equity vs Sector %

-200.2

Return on Equity vs Industry %

-183.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

466.1

◆ INSM Healthcare

$163.03

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

10/25

Volume

11/15

Valuation

13/20

TP/AR

6/10

Options

7/10

RSI

61.9

Range 1M

88.5%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

21/30

Estimates

7/20

Inst/Vol

1/15

Options

9/10

EPS Yr

58.7%

EPS NY

138.6%

52W%

67.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -52.1% upside

Quality

6/30

Valuation

0/30

Growth

16/25

Stability

6/10

LT Trend

2/5

Upside

-52.1%

Quality

Insmed Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 1664

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

INSM

Latest News

—

Caricamento notizie per INSM…

stock quote shares INSM – Insmed Incorporated Stock Price stock today

news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch INSM – Insmed Incorporated yahoo finance google finance

stock history INSM – Insmed Incorporated invest stock market

stock prices INSM premarket after hours

ticker INSM fair value insiders trading

INSM – Insmed Incorporated

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: INSM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y